UPC vs VERU

Universe Pharmaceuticals Inc vs Veru Inc. — Valuation Comparison 2026

UPC

Pharmaceutical Preparations
Universe Pharmaceuticals Inc
Quality
1.5
out of 10
Value Trap
15
SAFE
Price
$3.50
Last close
Models
4/13
Active
VS

VERU

Pharmaceutical Preparations
Veru Inc.
Quality
4.6
out of 10
Value Trap
25
LOW
Price
$2.37
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType UPC Fair ValueUPC Upside VERU Fair ValueVERU Upside
Bayesian DCF Intrinsic $0.53 -84.7% $1.44 -39.1%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $3.71 +56.7%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $9.06 +235.7%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for UPC vs VERU — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

UPC vs VERU — Which Stock Is More Undervalued?

VERU scores higher with a 4.6/10 quality rating vs UPC's 1.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Universe Pharmaceuticals Inc (UPC) and Veru Inc. (VERU) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

UPC currently trades at $3.50 with a QOC of 1.5/10, while VERU trades at $2.37 with a QOC of 4.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).